Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Communication

    EGFR Isoforms Might be Responsible for the Diminished Treatment Outcome of EGFR Inhibitors

    Rajdeep Chakraborty1,2★, Pallavi Khodlan1, Arthur Chien3, Chao Shen3, Thiri Zaw4, Matthew Fitzhenry4, Ardeshir Amirkhani4, Fei Liu2★ Corresponding author

    1. 1Applied Biosciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
    2. 2School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
    3. 3Macquarie Analytical & Fabrication Facility, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
    4. 4Australian Proteome Analysis Facility, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.

    CORRESPONDENCE

    Rajdeep Chakraborty

    Applied Biosciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.

    rajdeep.chakraborty@mq.edu.au

    Received: 16-03-2024; Accepted: 31-01-2025.

    Volume 17, Issue 1 · pp. 145–147 · PUBLISHED 2026 · DOI: 10.1177/0976500X251321892

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Epidermal growth factor receptor (EGFR) plays an active role during the progression of oral squamous cell carcinoma (OSCC). OSCC is the most common head and neck cancer. Cetuximab, which is an inhibitor of EGFR, was approved by the Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. After initial clinical success, Cetuximab proved to be ineffective in the management of aggressive or metastatic oral cancer lesions. We hypothesize that EGFR has multiple isoforms that lead to the failure of Cetuximab. A future study of EGFR isoforms and protein-interacting partners will address the issue.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Chakraborty, R., Khodlan, P., Chien, A., Shen, C., Zaw, T., Fitzhenry, M., Amirkhani, A., & Liu, F. (2026). EGFR Isoforms Might be Responsible for the Diminished Treatment Outcome of EGFR Inhibitors. Journal of Pharmacology and Pharmacotherapeutics, 17(1), 145–147. https://doi.org/10.1177/0976500X251321892